Jaguar Health Inc (JAGX) stock is higher by 142.86% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With JAGX Stock Today?
Jaguar Health Inc (JAGX) stock has gained 45.64% while the S&P 500 is unmoved 0% as of 11:54 AM on Tuesday, Dec 1. JAGX has risen $0.16 from the previous closing price of $0.35 on volume of 186,019,829 shares. Over the past year the S&P 500 is higher by 16.84% while JAGX is lower by -23.88%. JAGX lost -$1.89 per share in the over the last 12 months.
More About Jaguar Health Inc
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products. The company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the marketplace from plants used traditionally in rainforest areas. It operates into two business segments namely Human health and animal health. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.